

## Product datasheet for **TL307162V**

### Signal peptide peptidase like 2B (SPPL2B) Human shRNA Lentiviral Particle (Locus ID 56928)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Signal peptide peptidase like 2B (SPPL2B) Human shRNA Lentiviral Particle (Locus ID 56928)
Locus ID:	56928
Synonyms:	IMP-4; IMP4; PSH4; PSL1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	SPPL2B - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_001077238</a> , <a href="#">NM_020172</a> , <a href="#">NM_152988</a> , <a href="#">NM_001077238.1</a> , <a href="#">NM_152988.1</a> , <a href="#">NM_152988.2</a> , <a href="#">NM_020172.1</a> , <a href="#">BC028391</a> , <a href="#">BC028391.2</a> , <a href="#">BC001788</a> , <a href="#">BC093046</a> , <a href="#">NM_001077238.2</a>
UniProt ID:	<a href="#">Q8TCT7</a>
Summary:	This gene encodes a member of the GXGD family of aspartic proteases. The GXGD proteases are transmembrane proteins with two conserved catalytic motifs localized within the membrane-spanning regions. This enzyme localizes to endosomes, lysosomes, and the plasma membrane. It cleaves the transmembrane domain of tumor necrosis factor alpha to release the intracellular domain, which triggers cytokine expression in the innate and adaptive immunity pathways. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).